docetaxel trihydrate
docetaxel trihydrate structure
|
Common Name | docetaxel trihydrate | ||
|---|---|---|---|---|
| CAS Number | 148408-66-6 | Molecular Weight | 861.925 | |
| Density | 1.37 g/cm3 | Boiling Point | 1016.9ºC at 760 mmHg | |
| Molecular Formula | C43H59NO17 | Melting Point | 186-192ºC | |
| MSDS | N/A | Flash Point | 568.8ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
Clin. Cancer Res. 13(24) , 7487-95, (2007) Vascular endothelial growth factor (VEGF) is critical for angiogenesis and tumor progression; however, its role in endometrial cancer is not fully known. Therefore, we examined the clinical and therapeutic significance of VEGF in endometrial carcinoma using p... |
|
|
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.
Ann. Oncol. 21(10) , 1999-2004, (2010) Bevacizumab has demonstrated antitumor activity in multiple diseases. This phase II study was undertaken to determine the effects of adding bevacizumab to a regimen of docetaxel and oxaliplatin in patients with advanced adenocarcinoma of the stomach or gastro... |
|
|
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer.
Clin. Cancer Res. 14(18) , 5893-9, (2008) To identify biomarkers and gene expression profile signatures to distinguish patients with partial response (PR) from those with stable disease (SD) and progressive disease (PD).Twenty patients with inflammatory breast cancer and one patient with locally adva... |
|
|
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study
Eur. J. Surg. Oncol. 35(10) , 1048-54, (2009) Purpose To evaluate the triplet combination of bevacizumab, capecitabine and docetaxel (XTA) as neoadjuvant therapy for breast cancer. |
|
|
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Breast Cancer Res. Treat. 122(1) , 181-8, (2010) Long-term bisphosphonate therapy is associated with increased risk of osteonecrosis of the jaw (ONJ). In a retrospective analysis, a 16% ONJ incidence was reported in patients receiving bisphosphonates with anti-angiogenic therapy (bevacizumab or sunitinib) f... |
|
|
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer.
J. Clin. Oncol. 28(30) , 4562-7, (2010) To assess whether the low incidence of severe neutropenia in castrated men with prostate cancer treated with docetaxel is the result of changes in systemic clearance.A total of 10 noncastrated and 20 castrated men with prostate cancer were studied to achieve ... |